MOVING SCIENCE FORWARD
MultiPark is a strategic research area funded by the Swedish Government. The aim of the MultiPark project is to radically improve life for patients suffering from Parkinson’s disease. In a multidisciplinary mobilization neuroscientists are cooperating with researchers from nanotechnology, chemistry, physics and computer science. A union between experimental and clinical science is at the core of the overarching MultiPark vision – improving the quality of life for Parkinson patients.
The majority of our brain cells are formed in the embryonic stage. However, there are a few structures in the brain where new neurons continue to form throughout adulthood. A MultiPark research group has studied such a population of neurons and discovered that they can be guided towards building more advanced paths of communication with their surrounding environment. An increased understanding of the function of newborn brain cells could eventually explain the underlying causes of various diseases of the brain and open up for new treatments.
Normally, a thesis flies well below the radar of the broader scientific community. This one doesn’t. Each of the key findings in Olof Torper’s thesis has raised eyebrows among researchers worldwide. The concept of direct conversion is one that translates well into layman’s terms and as a result the science presented has also caught the media’s attention.
A new study from MultiPark researchers, in collaboration with Nobel Prize winner Paul Greengard, presents an exhaustive mapping of the circuits that are involved in the development dyskinesia in Parkinson's disease. The involuntary movements are the main drawback of the one major pharmacotherapy for Parkinson's existing today, L-Dopa.